目的 觀察注射用丹參多酚酸治療急性腦梗死臨床療效。方法 選擇2017年9月—2018年7月哈爾濱市第二醫(yī)院神經(jīng)內(nèi)科收治的急性腦梗死患者86例為研究對象。使用統(tǒng)計軟件隨機(jī)數(shù)字法將患者分為對照組和觀察組，每組各43例。對照組實施臨床常規(guī)治療，觀察組在對照組的基礎(chǔ)上給予注射用丹參多酚酸，將其溶于250 mL生理鹽水中進(jìn)行靜脈滴注給藥，1次/d。兩組均持續(xù)用藥治療14 d。分別比較兩組患者治療前后臨床療效、美國國立衛(wèi)生研究院卒中量表（NIHSS）評分及日常生活能力量表巴氏指數(shù)（BI）評分。結(jié)果 治療后，觀察組臨床療效為79.07%，顯著高于對照組的53.49%（P<0.05）。治療后，對照組與觀察組患者NIHSS評分與治療前比較顯著降低，BI評分與治療前比較升高，差異有統(tǒng)計學(xué)意義（P<0.05）；觀察組患者NIHSS評分和BI評分顯著優(yōu)于對照組，差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 注射用丹參多酚酸能改善急性腦梗死患者腦血管的血流動力學(xué)，有效改善缺血等癥狀，臨床療效確切，具有一定的臨床推廣價值。

Objective To observe the clinical efficacy of Salvianolate for injection in treatment of acute cerebral infarction. Methods Patients (86 cases) with acute cerebral infarction from September 2017 to July 2018 in the department of neurology, Harbin Second Hospital were randomly divided into control group and observation group, 43 cases of patients in each group. Patients in the control group were received routine clinical treatment, and patients in the observation group were iv administered with Salvianolate for injection on the basis of the control group, which was dissolved in 250 mL normal saline for once daily. Both groups were treated for 14 d. The clinical efficacy, NIHSS score, and BI score of the two groups were compared before and after treatment. Results After treatment, the clinical efficacy in the observation group was 79.07%, which was significantly higher than 53.49% in the control group (P < 0.05). After treatment, the NIHSS score of the control group and the observation group were significantly decreased compared with that before treatment, and the BI score were increased, with statistically significant difference (P < 0.05). The NIHSS and BI score of the observation group was significantly better than that of the control group, and the difference was statistically significant (P < 0.05). Conclusion Salvianolate for injection can improve the hemodynamics of cerebral vessels in patients with acute cerebral infarction, effectively improve the symptoms of ischemia and other symptoms, clinical efficacy is accurate, which has a certain clinical promotion value.

R969.4